



Practice for Retrieval and Analysis of Implanted Medical Devices, and Associated Tissues¹

This standard is issued under the fixed designation F 561; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This practice covers recommendations for the retrieval, handling, and analysis of implantable medical devices and associated specimens which are removed from patients, during revision surgery, at postmortem, or as part of animal studies. The aim is to provide guidance in preventing damage to the associated specimens which could obscure the investigational results, and in gathering data at the proper time and circumstance to validate the study.

1.2 This practice offers guidelines for the analysis of retrieved implants to limit damage to them, and to allow comparisons between investigational results from different studies. The protocols are divided into three stages, where Stage I is the minimum non-destructive analysis, Stage II is more complete non-destructive analysis, and Stage III is destructive analysis. Standard protocols for the examination and collection of data are provided for specific types of materials in relation to their typical applications. For particular investigational programs, additional, more specific, protocols may be required. If special analytical techniques are employed, the appropriate handling procedures must be specified.

1.3 This practice recommendation should be applied in accordance with national regulations or legal requirements regarding the handling and analysis of retrieved implants and excised tissues, especially with regard to handling devices which may become involved in litigation, as per Practice E 860.

1.4 A significant portion of the information associated with a retrieved implant device is often at the device-tissue interface or in the tissues associated with the implant and related organ systems. Attention should be given to the handling of adjacent tissues, so as not to interfere with study of the particles in the adjacent tissue, a chemical analysis for the byproducts of degradation of the implant, or a study of the cellular response to the implant.

1.5 *This standard may involve hazardous materials, operations, and equipment. As a precautionary measure, removed implants should be sterilized or minimally disinfected by an*

appropriate means that does not adversely affect the implant or the associated tissue that may be subject to subsequent analysis. This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

2. Referenced Documents

2.1 ASTM Standards:

- A 262 Practices for Detecting Susceptibility to Intergranular Attack in Austenitic Stainless Steels²
- A 751 Test Methods, Practices and Terminology for Chemical Analysis of Steel Products²
- C 20 Test Methods for Apparent Porosity, Water Absorption, Apparent Specific Gravity and Bulk Density of Burned Refractory Brick and Shapes by Boiling Water³
- C 158 Test Methods for Strength of Glass (Determination of Modulus of Rupture)⁴
- C 169 Test Methods for Chemical Analysis of Soda-Lime and Borosilicate Glass⁴
- C 573 Test Methods for Chemical Analysis of Fireclay and High-Alumina Refractories⁵
- C 623 Test Method for Young's Modulus, Shear Modulus, and Poisson's ratio for Glass and Glass-Ceramics by Resonance⁴
- C 633 Test Method for Adhesion or Cohesive Strength of Flame-Sprayed Coatings⁶
- C 674 Test Methods for Flexural Properties of Ceramic White Ware Materials⁴
- C 730 Test Method for Knoop Indentation Hardness of Glass⁴
- C 849 Test Method for Knoop Indentation Hardness of Ceramic Whitewares⁴
- C 1069 Test Method for Specific Surface Area of Alumina or Quartz by Nitrogen Adsorption⁴
- C 1161 Test Method for Flexural Strength—Advanced Ceramics at Ambient Temperatures³
- C 1198 Test Method for Dynamic Young's Modulus, Shear

¹ This practice is under the jurisdiction of ASTM Committee F-4 on Medical and Surgical Materials and Devices, and is the direct responsibility of Subcommittee F04.18 on Device Retrieval Analysis.

Current edition approved Dec. 10, 1997. Published June 1998. Originally published as F 561 – 78. Last previous edition F 561 – 87 (1994).

² *Annual Book of ASTM Standards*, Vol 01.03.

³ *Annual Book of ASTM Standards*, Vol 15.01.

⁴ *Annual Book of ASTM Standards*, Vol 15.02.

⁵ Discontinued—See 1994 *Annual Book of ASTM Standards*, Vol 03.05.

⁶ *Annual Book of ASTM Standards*, Vol 02.05.

 **F 561**

- Modulus, and Poisson's Ratio for Advanced Ceramics by Sonic Resonance³
- D 256 Test Methods for Determining the Izod Pendulum Impact Resistance of Plastics⁷
- D 412 Test Methods for Vulcanized Rubber and Thermoplastic Elastomers-Tension⁷
- D 570 Test Method for Water Absorption of Plastics⁷
- D 621 Test Methods for Deformation of Plastics Under Load⁷
- D 624 Test methods for Tear Strength of Conventional Vulcanized Rubber and Thermoplastic Elastomers⁸
- D 638 Test Method for Tensile Properties of Plastics⁷
- D 671 Test Method for Flexural Fatigue of Plastics by Constant Amplitude of Force⁷
- D 695 Test Method for Compressive Properties of Rigid Plastics⁷
- D 732 Test Method for Shear Strength of Plastics by Punch Tool⁷
- D 747 Test Method for Apparent Bending Modulus of Plastics by Means of a Cantilever Beam⁷
- D 785 Test Method for Rockwell Hardness of Plastics and Electrical Insulating Materials⁷
- D 790 Test Methods for Flexural Properties of Unreinforced and Reinforced Plastics and Electrical Insulating Materials⁷
- D 792 Test Methods for Density and Specific Gravity (Relative Density) of Plastics by Displacement⁷
- D 1004 Test Method for Initial Tear Resistance of Plastic Film and Sheeting⁷
- D 1042 Test Method for Linear Dimensional Changes of Plastics Under Accelerated Service Conditions⁷
- D 1238 Test Method for Flow Rates of Thermoplastics by Extrusion Plastometer⁷
- D 1239 Test Method for Resistance of Plastic Films to Extraction by Chemicals⁷
- D 1242 Test Methods for Resistance of Plastic Materials to Abrasion⁷
- D 1505 Test Method for Density of Plastics by the Density—Gradient Technique⁷
- D 1621 Test Method for Compressive Properties of Rigid Cellular Plastics⁷
- D 1622 Test Method for Apparent Density of Rigid Cellular Plastics⁷
- D 1623 Test Method for Tensile and Tensile Adhesion Properties of Rigid Cellular Plastics⁷
- D 1708 Test Method for Tensile Properties of Plastics by Use of Micro Tensile Specimens⁷
- D 2240 Test Method for Rubber Property—Durometer Hardness⁷
- D 2842 Test Method for Water Absorption of Rigid Cellular Plastics⁹
- D 2857 Test Method for Dilute Solution Viscosity of Polymers⁹
- D 2873 Test Method for Interior Porosity of Poly(Vinyl Chloride) (PVC) Resins by Mercury Intrusion Porosimetry⁹
- D 2990 Test Methods for Tensile, Compressive, and Flexural Creep and Creep-Rupture of Plastics⁹
- D 3016 Practice for Use of Liquid Exclusion Chromatography Terms and Relationships⁹
- D 3417 Test Methods for Heats of Fusion and Crystallization of Polymers by Thermal Analysis⁹
- D 3418 Test Method for Transition Temperatures of Polymers by Thermal Analysis⁹
- D 3835 Test Method for Determination of Properties of Polymeric Materials by Means of a Capillary Rheometer⁹
- D 3919 Practice for Measuring Trace Elements in Water by Graphite Furnace Atomic Absorption Spectrophotometry¹⁰
- D 4000 Classification System for Specifying Plastic Materials⁹
- D 4001 Test Method for Determination of Weight-Average Molecular Weight by Light Scattering¹¹
- D 4065 Practice for Determining and Reporting Dynamic Mechanical Properties of Plastics⁹
- D 4754 Test Method for Two-Sided Liquid Extraction of Plastic Materials Using FDA Migration Cell¹¹
- D 5152 Practice for Water Extraction of Residual Solids from Degraded Plastics for Toxicity Testing¹¹
- D 5227 Test Method for the Measurement of Hexane Extractable Content of Polyolefins¹¹
- D 5296 Test Method for Molecular Weight Averages and Molecular Weight Distribution of Polystyrene by High Performance Size-Exclusion Chromatography⁹
- E 3 Methods of Preparation of Metallographic Specimens¹²
- E 7 Terminology Relating to Metallography¹²
- E 8 Test Methods for Tension Testing of Metallic Materials¹²
- E 10 Test Method for Brinell Hardness of Metallic Materials¹²
- E 18 Test Methods for Rockwell Hardness and Rockwell Superficial Hardness of Metallic Materials¹²
- E 45 Test Methods for Determining the Inclusion Content of Steel¹²
- E 92 Test Method for Vickers Hardness of Metallic Materials¹²
- E 112 Test Methods for Determining the Average Grain Size¹²
- E 120 Test Methods for Chemical Analysis of Titanium and Titanium Alloys¹³
- E 135 Terminology Relating to Analytical Chemistry for Metals, Ores, and Related Materials¹³
- E 168 Practices for General Techniques of Infrared Quantitative Analysis¹⁴
- E 204 Practices for Identification of Materials by Infrared Absorption Spectroscopy Using the ASTM Coded Band and Chemical Classification Index¹²

⁷ Annual Book of ASTM Standards, Vol 08.01.

⁸ Annual Book of ASTM Standards, Vol 09.01.

⁹ Annual Book of ASTM Standards, Vol 08.02.

¹⁰ Annual Book of ASTM Standards, Vol 11.01.

¹¹ Annual Book of ASTM Standards, Vol 08.03.

¹² Annual Book of ASTM Standards, Vol 03.01.

¹³ Annual Book of ASTM Standards, Vol 03.05.

¹⁴ Annual Book of ASTM Standards, Vol 03.06.

- E 290 Test Method for Bend Testing of Material for Ductility¹²
- E 353 Test Methods for Chemical Analysis of Stainless, Heat-Resisting, Maraging, and Other Similar Chromium-Nickel-Iron Alloys¹³
- E 354 Test Methods for Chemical Analysis of High-Temperature, Electrical, Magnetic, and Other Similar Iron, Nickel, and Cobalt Alloys¹³
- E 386 Practice for Data Presentation Relating to High Resolution Nuclear Magnetic Resonance (NMR) Spectroscopy¹⁵
- E 407 Practice for Microetching of Metals and Alloys¹²
- E 562 Practice for Determining Volume Fraction by Systematic Manual Point Count¹²
- E 663 Practice for Flame Atomic Absorption Spectroscopy¹⁴
- E 860 Practice for Examining and Testing Items that are or May Become Involved in Products Liability Litigation¹⁴
- E 883 Guide for Reflected-Light Photomicrography¹²
- E 986 Practice for Scanning Electron Microscope Beam Size Characterization¹²
- E 1188 Practice for Collection and Preservation of Information and Physical Items by a Technical Investigator¹⁶
- E 1452 Practice for Preparation of Calibration Solutions for Spectrophotometric and for Spectroscopic Atomic Analyses¹⁴
- E 1479 Practice for Describing and Specifying Inductively-Coupled Plasma Optical Emission Spectrophotometers¹⁴
- F 316 Test Method for Pore Size Characteristics of Membrane Filters for Use with Aerospace Fluids¹⁰
- F 619 Practice for Extraction of Medical Plastics¹⁷
- F 981 Assessment of Compatibility of Biomaterials for Surgical Implants with Respect to Effect of Materials on Muscle and Bone¹⁷
- F 1044 Test Method for Shear Testing of Porous Metal Coatings¹⁷
- F 1147 Test Method for Tension Testing of Porous Metal Coatings¹⁷
- F 1501 Test Method for Tension Testing of Calcium Phosphate Coatings¹⁷
- F 1658 Test Method for Shear Testing of Calcium Phosphate Coatings¹⁷

2.2 Other Document:

ISO/DIS 12891-1, Retrieval and Analysis of Implantable Medical Devices, Part 1: Standard Practice for Retrieval and Handling

3. Terminology

3.1 *Definition of Terms Specific to Issues of Microbial Contamination:*

3.1.1 *antiseptic*—a germicide that is used on skin or living tissue for the purposes of inhibiting or destroying microorganisms.

3.1.2 *decontamination*—a process or treatment that renders

a medical device, instrument, or environmental surface safe to handle. Ranges from sterilization to cleaning with soap and water.

3.1.3 *disinfectant*—a germicide that is used solely for destroying microorganisms on inanimate objects.

3.1.4 *disinfection*—generally less lethal than sterilization. It eliminates virtually all recognized pathogenic microorganisms but not necessarily all microbial forms (e.g., bacterial endospores) on inanimate objects. It does not insure overkill.

3.1.5 *sterilization*—use of a physical or chemical procedure to destroy all microbial life; including large numbers of highly resistant bacterial endospores.

4. Summary of Practice

4.1 This practice provides recommendations for collection of clinical data, analysis of adjacent tissues and the material characterizations to be performed when an implant is retrieved as part of a clinical or an animal study.

4.2 The clinical data to be recorded include a case history review, roentgenogram reviews, tissue culture, and observations of the implant site.

4.3 Protocols are provided for the handling of the implant tissue interface, and adjacent tissues for subsequent analysis. These protocols are intended to facilitate (a) histologic and immunohistochemical examination of the tissues, (b) chemical analysis of the tissues for identification and quantification of implant corrosion or degradation products, and (c) digestion of tissues for subsequent harvesting and analysis of particulate debris.

4.4 The material characterizations include observation and description of the explanted device and adjacent tissues, determination of chemical composition, macroscopic and microscopic examinations and mechanical property determinations. The guidelines are separated in three stages. Stage I is considered to comprise an essential minimum analysis for routine examination of all types of materials. Stage II is nondestructive but provides more detail and is intended for special studies of devices with or without impaired function, made of all types of materials. Stage III includes destructive methods for and material-specific protocols for detailed failure, microstructural, and chemical analysis as well as determination of physical and mechanical properties.

5. Significance and Use

5.1 The investigation of retrieved implantable medical devices and adjacent tissues can be of value in the assessment of clinical complications associated with the use of a specific prosthetic device design; can expand the knowledge of clinical implant performance and interactions between implants and the body; provide information on implant performance and safety; and thus further the development of biocompatible implant materials and devices with improved performance.

5.2 A significant portion of the information associated with a retrieved implant is obtained with detailed studies of the device-tissue interface. Appropriate methods are provided to facilitate a study of the particles in the tissues, and chemical analysis for the byproducts of degradation of the implant, and histologic evaluation of the cellular response to the implant.

5.3 For the analysis to be accurate, it is essential that the

¹⁵ Annual Book of ASTM Standards, Vol 14.02.

¹⁶ Annual Book of ASTM Standards, Vol 13.01.

¹⁷ Available from American National Standards Institute, 1430 Broadway, New York, NY 10018.

device and associated tissues be removed without alteration of their form and structure. It is also essential that the tissues be handled in such a way as to avoid microbial contamination of the work place or the investigator. Standard protocols for the examination and collection of data are provided for retrieval and handling of implantable medical devices, as well as for specific types of materials in relation to their typical applications. For particular investigational programs, additional, more specific, protocols may be required. If special analytical techniques are employed, the appropriate procedures must be specified.

5.4 In order to interpret the analysis of materials and tissues, it is also essential to capture a minimum data set regarding the clinical findings and laboratory studies documenting device performance and reasons for removal.

5.5 Any destructive analysis of implants must be done so as to not destroy any features that may become the subject of litigation, as per Practice E 860. This standard recommendation should be applied in accordance with state or national regulations or legal requirements regarding the handling and analysis of retrieved implants and tissues.

6. Interferences

6.1 Some critical features of the retrieved implant, tissue and the interface can only be accurately described by observation at the time of removal, and prior to sterilization or disinfection. Such observation must be made using appropriate aseptic precautions.

6.2 Due to the destructive nature of some of the analysis protocols provided in this practice, their use precludes any other type of analysis. It is therefore essential that handling of the device and tissues be done in concert with the requirements of all of the analyses to be performed, including analyses that may be done in the future.

7. Hazards

7.1 The handling of retrieved implants and tissues may involve handling of infectious material.

7.2 It is suggested that individuals handling the devices be vaccinated against Hepatitis B. As a precautionary measure, removed implants should be sterilized by an appropriate means that does not adversely affect the implant.

7.3 There are situations where tissues or implants can not be sterilized or disinfected prior to analysis, for example, requirements of specialized protocols in which sterilization will adversely effect tissue or material properties. In such cases, extreme care should be taken to use aseptic technique and disinfection. Where institutional guidelines for the handling of septic material do not exist, details for handling and sterilizing retrievals, and laboratory practice recommendations can be found in ISO 12891-1.

8. Clinical Information Gathered at the Time of Implant Explantation

8.1 The extent of clinical information to be obtained will depend in part on the type of implant and reasons for removal. Similarly, the amount of information provided about the implant site will depend on the circumstances regarding the removal. A detailed listing and format for documentation of the

clinical information associated with removal are provided in Appendix X1.

8.2 As a minimum, the clinical information for device tracking should include the following information:

8.2.1 Date of implantation, and date of explantation.

8.2.2 Identification of hospitals, or physicians' offices, where device implantation and removal was performed.

8.2.3 Confidential, unique, patient ID Code to link to hospitals implantation and removal records.

8.2.4 Device identification (manufacturer's name and device catalogue number).

8.2.5 Device lot and serial number.

8.2.6 Indication for use and reason for explantation (clinical diagnosis).

8.3 For purposes of implant retrieval studies, the following information is considered essential:

8.3.1 Patient or animal age and sex.

8.3.2 A generic statement as to level of patient activity relative to the device.

8.3.3 A statement as to any gross evidence of inflammation, implant site infection, or tissue damage such as osteolysis.

8.3.4 Orientation of the implant relative to the patient. It is suggested that the proximal end of the device be identified with a nondestructive marking scheme.

8.4 More detailed clinical information should be gathered, where feasible, as indicated in Appendix X1. Obtaining an in situ, intraoperative photograph of the implant is highly desirable.

8.5 To facilitate subsequent analysis, it is recommended that the device be removed with the tissue interface intact.

8.5.1 In cases of animal studies of tissue responses to implants, the implant should be removed with at least a 4 mm thick layer of adjacent tissue, as per F 981.

9. Analysis of the Tissues and the Tissue-Implant Interface

9.1 *Macroscopic Examination of Tissue:*

9.1.1 Record a gross pathologic description of the tissue immediately adjacent to the implant, as to consistency and color, as seen by the naked eye, or with a hand lens or dissecting microscope. Record any differences between the implant-tissue interface and the tissues not in direct contact with the implant. Describe the specimen size either by dimensions or weight.

9.1.2 Since the color of tissue is altered by sterilization and fixation methods, it is recommended that gross observations be made prior to sterilization. Such observations should be made utilizing aseptic techniques.

9.1.3 Where appropriate and feasible, obtain photographic documentation of the explant and adjacent tissue, as well as a photographic record of subsequent dissections.

9.2 *Histopathological Analysis of Tissue:*

9.2.1 Process the excised tissue using standard laboratory procedures for the histological dehydration, embedding and sectioning. These procedures may be for paraffin embedding, methacrylate embedding or other special procedures. Routine staining with hematoxylin and eosin (H & E), or toluidine blue are recommended for light microscopy of soft tissues and bone.

 **F 561**

Special stains, for example, von Kassa, Masson, Movat pentachrome, may be utilized as indicated and should be fully described.

9.2.2 Provide a detailed histopathologic description of the tissue-implant interface as well as all adjacent tissue specimens, for example, extracellular matrix, necrotic changes, thickness of fibrous capsule, cell types, particulates, hyperplasia, dysplasia, type of inflammatory reaction.

9.2.3 If the implant material is porous, then tissue analysis must include evaluation of the reaction within the pores as well as in the adjacent tissues. This should include the degree and nature of tissue ingrowth, and biological fixation.

9.2.4 For detailed studies of tissue reactions, the use of a quantitative scoring scheme, such as that in Practice F 981 is recommended.

9.2.5 Since some polymeric materials, for example, PMMA bone cement, are altered or dissolved by the solutions used for routine histology, special techniques may be indicated, or special note made of voids formerly occupied by the material.

9.3 Immunohistochemical and Other Special Histopathology Protocols:

9.3.1 These procedures can be used for identifying specific cell types and extracellular matrix tissue responses to implantable materials and prosthetic devices. This field is constantly changing, and therefore only one such approach is provided as an example.

9.3.1.1 Typical markers chosen are for the presence of immunoglobulins on lymphocytes to indicate B cells or on monocytes/macrophages to indicate activation, the presence of CD2 markers to indicate immature T cells, the presence of CD3 markers to indicate mature T cells, and markers to indicate activated macrophages.

9.3.1.2 The protocols consist of a series of steps or reactions which have been developed to amplify the reactions, and to be cost effective. First, an antibody specific for the CD marker is used (typically mouse anti-human). Then, a biotinylated antibody to the first antibody is applied (typically goat anti-mouse); biotin serves as a marker in this amplification phase of the reactions. Strept-avidine peroxidase is then added to bind to the biotin and immobilize the peroxidase. Finally, a substrate is added which will react with the peroxidase, change color and precipitate. Diaminobenzidine (DAB) is often used, although several substrates are available for different kits or automatic systems. The end result is the peroxidase oxidation of DAB to give a yellow-brown precipitate at the site of the reaction. The sections can be stained with hematoxylin to enhance the visibility of cells.

9.3.1.3 An example of a method to be used is briefly summarized below and is based on standard techniques. Although it was originally described for use on frozen tissues, the use of embedded tissues allows for examination of the same tissue blocks used for routine pathology. This is only one of many approaches.

9.3.2 Reagents:

9.3.2.1 The reagents used come from a variety of companies including DAKO, Becton Dickinson, Kirkegaard & Perry, and Oncogene.

9.3.2.2 Antibody for specific markers, for example, CD2, CD3.

9.3.2.3 Biotinylated goat anti-mouse or anti-rabbit IgG.

9.3.2.4 Strept-avidine peroxidase.

9.3.2.5 Diaminobenzidine (DAB), or other suitable substrate.

9.3.3 Sections are deparaffinated in xylene for 5 min twice, and then rehydrated with absolute ethanol for 3 min, 95 % ethanol for 3 min, and then in 70 % ethanol for 3 min.

9.3.4 The sections are then placed in a methanol-hydrogen peroxide solution for 30 min to diminish the background level of peroxidase in the tissue. The sections are rinsed in water, next placed in buffered saline, and then the slide around the section is dried.

9.3.5 The slide is then placed in a humidity chamber, covered with buffer, and the first antibody is added. This will be the antibody specific for the marker (for example, CD2) and will be either of mouse or rabbit origin. This is incubated overnight, then rinsed with buffer, drained, and the slide around the tissue dried.

9.3.6 The second antibody, which is biotinylated, is added. This is usually goat anti-mouse or anti-rabbit IgG. This is incubated for 30 min, rinsed, the slide dried, and then strept-avidin peroxidase is added.

9.3.7 The strept-avidin peroxidase is incubated for 30 min, rinsed, and then a substrate such as DAB is added. The development of the color is watched under the microscope, the action stopped with water, then the slides are dipped into osmium tetroxide for final fixation. The slides may be counterstained with hematoxylin for visualization of all cells. The slides are processed for mounting with eukitt and can be evaluated for presence of label.

9.3.8 This method can be used to detect the production of cytokines in the cells in the tissues. However, caution should be used in the interpretation of findings, since these are soluble mediators and rapidly leave the site of origin.

9.4 Chemical Analysis of Tissues By Flame Atomic Absorption Spectroscopy (AAS), Graphite Furnace Atomic Absorption Spectroscopy (GFAAS), by Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) or Mass Spectroscopy (ICPMS):

9.4.1 Reagents and Materials:

9.4.1.1 Standard AAS grade solutions (MCB reagents, Fisher, and VWR) are used to make calibration curves. Calibration solutions should be prepared according to Practices E 1452 and D 3919, using the same matrix solution as the test specimen. Solutions of low concentration should be made fresh daily. The sensitivity and possible interferences depend on the particular element.

9.4.1.2 Any fixing agents, chemicals and solvents must be of analytic purity. The use of 70 % ethanol is recommended as a transport and storage solution. The use of double distilled, deionized water is necessary.

9.4.1.3 Handling of tissues for subsequent chemical analysis requires special precautions to be taken to insure that the specimens are not contaminated with the elements to be analyzed. Surgical knives or instruments used for tissue excision shall be free of any contamination or loose particulates.

The use of ceramic or glass knives is recommended for preparation of specimens associated with metallic implants. Glass knives are not recommended for subsequent silicone analysis.

9.4.1.4 Tissues should be transferred to plastic or glass containers of high quality which have been thoroughly acid cleaned or unused from a lot tested to be free of contamination. Acid cleaning which may etch the glass surfaces is not recommended for subsequent silicone analysis. Tissue transfer should be done in a dust free environment.

9.4.2 Test solutions should be analyzed in triplicate, either as is or after dilution with 1 % nitric acid to a concentration which falls within the standards, and the results averaged. Concentrations are determined in μl (ppb), or μg of tissue (ppm). Results from solutions of known volumes from *in vitro* studies can be converted to total micrograms in solution.

9.4.2.1 The concentration of metallic species in tissue may vary according to the location of the specimen relative to the implant. It is therefore important to carefully record the location of the specimen.

9.4.3 These methods of analysis require chemical digestion of the tissue samples prior to analysis, and therefore the samples can not be used for any other analysis. The ability to digest tissue is influenced by the method of tissue fixation. It is recommended that tissues be fixed in analytical grade 70 % ethanol in analytical grade water. The methods of digestion depend on the type of tissue to be analyzed.

9.4.3.1 *Blood* samples drawn from patients or animals should be done using polypropylene syringes. The blood can be allowed to clot at room temperature and centrifuged at 1850 g for 30 min to separate serum and clot fractions. Blood may also be drawn in heparinized vacutainer tubes. The blood may be allowed to settle so as to isolate red and white cells, or be centrifuged at 400 g and the plasma supernatant drawn off. Plasma is diluted at least 2 \times in 1 % nitric acid.

9.4.3.2 *Cells*, either red blood cells or cells from cell culture experiments may receive special treatment, such as separation of cell contents and cell membranes. The cells are washed and centrifuged 3 times with physiologic saline to remove trapped serum or growth media. The cell pellet is then lysed with 1 % Triton X100 to release intracellular contents, centrifuged and the supernatant harvested. This solution is pipetted off, diluted 2 \times in 1 % nitric acid, and referred to as "cell contents." The pellet of cell membranes is then washed and centrifuged 3 times in saline to remove the Triton and remaining contents. The membranes are then digested in 50 % nitric acid, diluted in 0.5 % nitric acid for analysis as "cell membranes."

9.4.3.3 *Tissue* from implant sites or joint capsules should be weighed and placed in plastic bags for the mechanical tissue digestion machine. These are then frozen until use. For preparation, 5 ml of 50 % nitric acid will be added to each bag. The tissue is then homogenized in a mechanical blender. The samples are then pipetted into the GFAAS for analysis. Dilution as necessary is done with nitric acid.

9.4.3.4 *Bone* specimens can be subjected to a two-stage digestion procedure to separate them into two phases, mineralized and demineralized (or organic). The bones are placed in 0.5 N HCl for 48 hrs at 4 $^{\circ}\text{C}$ to demineralize them. The rubbery

demineralized samples are then placed in 50 % nitric acid to digest the organic portion. Both the HCl and HNO₃ samples are diluted as necessary and analyzed by GFAAS.

9.4.4 Chemical analysis by flame AAS should be done according to manufacturer's instructions, in accordance with E 663 and E 135.

9.4.5 Analysis with graphite furnace (GFAAS) should be done according to D 3919 using the manufacturer's specifications for analyte wavelength and slit width. Calibration standards, as per E 1452, should be made up in the same matrix as the test specimens.

9.4.5.1 A multi-cycle protocol is recommended to insure complete drying of the specimen prior to charring and atomization; additional steps may be required for post analysis clearing of the tubes.

9.4.5.2 The use of ultra pure argon for clearing is essential.

9.4.5.3 There are two types of graphite tubes used in the furnace: pyrolytic carbon coated graphite tubes, and tubes with L'vov platforms. The analysis for Ni, Mo, Pt, Ti, and V are done from the wall of the tubes while Co, Cr and Al are done on platforms.

9.4.6 Chemical analysis by ICP should be done in accordance with Practice E 1479.

9.5 *Analysis of Tissues for Particulate Debris:*

9.5.1 Analysis for particulates can be done histopathologically as in 9.2, or by tissue or fluid digestion and particle separation. Tissues subjected to digestion become dedicated to this type of analysis.

9.5.1.1 Preparation of tissue for drying and digestion will depend on the state of the tissue. If the tissue is embedded in paraffin, the tissue block should be deparaffinized with xylene overnight at room temperature, and then washed with 100 % ethanol. If tissue is fixed in formalin, it should be dehydrated through a series of alcohols using standard histological protocol, and infiltrated with 100 % ethanol. If tissue is fresh, it should be frozen and free of embedding media.

9.5.1.2 The tissue will be weighed, or the fluid volume determined before digestion. If a wet weight is desired (only applicable for the fresh tissue), 0.3–0.5 g are typically weighed out. For a dry tissue weight, the tissue should be freeze dried, sliced with a ceramic knife, and 0.02–0.03 g weighed out with a microbalance. Weighed tissue should then be placed in acid washed polystyrene vials. Once weighed, the tissue is suitable for digestion.

9.5.1.3 Several digestion protocols are described in the literature. The choice of protocol depends in part on the type of particle of interest, for example, metal versus polymer, and on the type of tissue. Four methods of digestion are described in this recommended practice.

9.5.2 *Reagents for Digestion:*

9.5.2.1 *Ultrapure water*—Distilled H₂O filtered with 0.2 μm filter.

9.5.2.2 *Phosphate Buffer*—3.55 g Na₂HPO₄, 3.45 g NaH₂PO₄, 0.744 g EDTA, in 100 ml ultrapure water.

9.5.2.3 *Papain solution*—1 ml phosphate buffer, 100 μL pure papain, 3.26 mg N-acetylcysteine, 9 ml ultrapure water.

9.5.2.4 *Strong bases*—Tissues have been digested in solutions of sodium hydroxide ranging from 1–10 N NaOH (5–50